Ask AI
ProCE Banner Activity

HER2-Positive NSCLC Treatment

Slideset

Download this slideset featuring the latest data and expert insights on HER2 biomarker testing in NSCLC, individualized sequencing strategies for HER2-overexpressing NSCLC, and proactive adverse event management strategies.

Released: June 23, 2026

Share

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement evidence-based strategies for accurate HER2 biomarker testing in NSCLC, including appropriate use of IHC, ISH, and NGS, to ensure consistent identification and reporting of HER2 overexpression and guide selection of HER2-directed therapies

  • Plan individualized sequencing strategies for HER2-overexpressing NSCLC using current evidence and patient-centered considerations

  • Devise proactive measures for monitoring and managing adverse events associated with HER2-directed ADCs and tailor salvage therapy for relapsed HER2-overexpressing NSCLC